Liquent, a provider of software and service solutions for the regulatory business processes of life sciences companies, has been acquired by Marlin Equity Partners from Thomson Reuters.
Based in Los Angeles, Marlin is a private investment firm with over USD1b of capital under management.
Liquent is the provider of the regulatory information management platform Liquent InSight. InSight can be leveraged throughout a client organisation in support of a life sciences company’s development, registration, and manufacturing processes.
Through its regulatory and clinical services consulting services team, Liquent also provides a full range of outsourcing services to support the regulatory submission and registration management activities of a life sciences company.
Liquent’s current general manager, Rick Riegel, will continue his leadership position as the chief executive of the company.
"We are very excited to be partnering with such a strong private equity firm," says Riegel. "Marlin brings substantial financial resources and expertise in the healthcare IT sector. With their backing and Liquent’s comprehensive software and service solutions, industry leadership, and focus on customer service, we look forward to accelerating our growth and ability to service the evolving and rapidly changing needs of the life sciences industry."
"Marlin recognises the life sciences industry’s constant struggle with regulatory change, new product approvals, and cost pressures. Marlin’s backing combined with Liquent’s software and outsourcing capabilities positions us well in helping our customers solve complex regulatory challenges," adds Jim Brady, healthcare operating partner at Marlin Equity Partners.
